<DOC>
	<DOCNO>NCT01096290</DOCNO>
	<brief_summary>Constipation medication serious common condition . Lubiprostone property make candidate drug . One hundred volunteer constipation take medication know cause constipation randomize take lubiprostone placebo 28 day . Therapeutic outcome evaluate investigator study subject assessment .</brief_summary>
	<brief_title>Comparison Lubiprostone Placebo Relief Constipation From Constipating Medications</brief_title>
	<detailed_description>Lubiprostone novel chloride channel activator increase intestinal fluid secretion motility . It FDA approve indicated treatment chronic idiopathic constipation recently , constipation-predominant irritable bowel syndrome . The Physicians Desk Reference list 90 Brand medication report incidence associate constipation 3 % . Little data available treatment response . A recent publication group report treatment success medication constipation use polyethylene glycol . Since ongoing study address role lubiprostone opioid constipation , work enrol medication constipation study subject use opioids . In study , patient meet diagnostic criterion constipation randomize receive 28 day treatment lubiprostone 24mcg twice day . Data collect evaluate therapeutic outcome .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Adult male female outpatient age 19 old . Patients meet International Congress Gastroenterology ( ROME III ) clinical criterion constipation* : 1 . Must include two follow : 1 . Straining &gt; 1/4 defecation ; 2 . Lumpy hard stool &gt; 1/4 defecation ; 3 . Sensation incomplete evacuation 1/4 defecation ; 4 . Sensation anorectal obstruction/blockage &gt; 1/4 defecation ; 5 . &lt; 3 defecations/week . 2 . Loose stool rarely present without use laxative . 3 . There insufficient criterion irritable bowel syndrome . *Criteria fulfil last 3 month symptom onset least 6 month prior diagnosis . Use one listed medication know cause constipation . If female childbearing potential , patient must surgically sterilize use oral contraceptive , depot contraceptive , intrauterine device , testify monogamous vasectomized partner , practice abstinence continue duration study . Mandatory compliance require . Serum pregnancy test perform screen need followup . Negative result receive inclusion administration first study dose . If pregnancy occur trial , investigator notify immediately result prompt discontinuation . Study subject must receive lubiprostone 72 hour . Written informed consent . Known suspected obstruction , gastric retention , ileus , perforation , fecal impaction inflammatory bowel disease . Severe diarrhea . Prior small bowel colonic resection colostomy . Weight &lt; 80 lb . If patient constipation accord investigator 's clinical judgment result constipate medication suffer secondary cause include limited factor dietary , neurologic , congenital , diabetic hypothyroid . Positive stool hemoccult ( Can include colonoscopic evaluation subsequently negative ) . Significant cardiac , renal hepatic insufficiency . Pregnant expect become pregnant within 120 day study enrollment . Lactating breast feeding . Subjects use opioid medication . Subjects opinion investigator would unable comply adequately study plan . Use investigational drug last 30 day . Patients know allergy lubiprostone .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>constipation</keyword>
	<keyword>lubiprostone</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>